Kiniksa Pharmaceuticals (KNSA) director gains shares and new equity awards
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kiniksa Pharmaceuticals International, plc director Cole G. Bradley reported equity compensation transactions. Bradley exercised 2,799 Restricted Share Units that vested in a single installment into the same number of Class A Ordinary Shares, bringing his direct holdings to 15,345 shares. He also received 2,026 new Restricted Share Units that each represent one Class A Ordinary Share, vesting in full on the earlier of the grant anniversary or the next annual shareholder meeting. In addition, he was granted options on 12,158 Class A Ordinary Shares at an exercise price of $48.38 per share, vesting in twelve substantially equal monthly installments and expiring in 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
2,799 shares exercised/converted
Mixed
4 txns
Insider
Cole G Bradley
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Share Option | 12,158 | $0.00 | -- |
| Grant/Award | Restricted Share Units | 2,026 | $0.00 | -- |
| Exercise | Restricted Share Units | 2,799 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 2,799 | $0.00 | -- |
Holdings After Transaction:
Share Option — 12,158 shares (Direct, null);
Restricted Share Units — 2,026 shares (Direct, null);
Class A Ordinary Share — 15,345 shares (Direct, null)
Footnotes (1)
- Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.
Key Figures
RSUs exercised into shares: 2,799 shares
Shares held after transactions: 15,345 shares
New RSUs granted: 2,026 RSUs
+4 more
7 metrics
RSUs exercised into shares
2,799 shares
Class A Ordinary Shares acquired via RSU vesting on May 29, 2026
Shares held after transactions
15,345 shares
Direct Class A Ordinary Share holdings following RSU exercise
New RSUs granted
2,026 RSUs
Each RSU represents one Class A Ordinary Share, granted May 29, 2026
New options granted
12,158 options
Share options on Class A Ordinary Shares granted May 29, 2026
Option exercise price
$48.38 per share
Conversion or exercise price for 12,158 share options
Option expiration date
May 28, 2036
Expiration for the 12,158 granted share options
Derivative exercise shares
2,799 shares
Total shares underlying derivative securities exercised in this filing
Key Terms
Restricted Share Unit (RSU), Class A Ordinary Share, Share Option, vests and becomes exercisable, +1 more
5 terms
vests and becomes exercisable financial
"The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant"
FAQ
What insider transactions did Kiniksa (KNSA) director Cole G. Bradley report?
Cole G. Bradley reported equity compensation activity, including exercising 2,799 Restricted Share Units into Class A Ordinary Shares and receiving new grants of 2,026 RSUs and 12,158 share options as part of his director compensation package.
How did the vested Kiniksa (KNSA) RSUs affect Cole G. Bradley’s derivative holdings?
The 2,799 Restricted Share Units vested in a single installment and were fully converted into Class A Ordinary Shares, leaving zero RSUs from that grant outstanding. This is reflected by the derivative position for those RSUs dropping to 0 in the Form 4 data.